Special Issue "EBV and Autoimmune Disease"
Deadline for manuscript submissions: closed (30 September 2021) | Viewed by 2269
Epstein–Barr Virus (EBV), the first human tumor virus, was identified more than 50 years ago.
Primary infection generally occurs in the oropharynx; EBV then crosses the basal membrane of oral epithelium to reach B lymphocytes, into which it establishes a lifelong latent infection. EBV reactivation from latency induces host cells to differentiate into plasma cells as the virus starts expressing proteins of the lytic cycle to produce infectious progeny.
Whilst much of what is known about EBV comes from its association with cancer, emerging evidence suggests that the virus may also play a critical role in pathogenesis of several autoimmune diseases, thus adding another complexity to the mosaic of autoimmunity. The large diffusion of this virus (95% people worldwide are infected) and the fact that EBV lodges in B lymphocytes, fundamental for adaptive humoral immunity, suggest a delicate balance between the virus and immune responses. Decades of research into how EBV escapes immune eradication has provided important information regarding the virus–host interaction, but the new challenge today is to clarify how EBV controls and triggers immune response and, as a consequence, sometimes leads to aberrant autoimmune reactions.
The aim of this Special Issue is to provide insights into the interaction between EBV and autoimmune diseases. To this end, I would like to invite you to submit your research/review articles, and short communications related to EBV and Autoimmunity.
As a Guest Editor of this Special Issue, I look forward to reviewing your submissions and, together, defining the present state of the art as to how this common herpesvirus contributes to debilitating autoimmune diseases.
Dr. Antonella Farina
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Epstein–Barr and immune response
- systemic sclerosis, multiple sclerosis
- systemic autoimmune diseases